✉ Email this page to a colleague
« Back to Dashboard
▶ Start for $1
Remove trial restrictions
Vatalanib is an investigational drug.
There have been 24 clinical trials for Vatalanib. The most recent clinical trial was a Phase 3 trial, which was initiated on February 1st 2003.
The most common disease conditions in clinical trials are Carcinoid Tumor, Neoplasms, and Neuroendocrine Tumors. The leading clinical trial sponsors are Novartis, National Cancer Institute (NCI), and Novartis Pharmaceuticals.
Recent Clinical Trials for Vatalanib
|Exploratory Clinical Study of Apatinib and SHR-1210 in Treating Advanced Hepatocellular Carcinoma or Gastric Cancer||The Affiliated Hospital of the Chinese Academy of Military Medical Sciences||Phase 1/Phase 2|
|Apatinib for Metastatic Esophageal Cancer.||Hangzhou Cancer Hospital||Phase 2|
|Vatalanib and Pemetrexed Disodium in Treating Patients With Advanced Solid Tumors||National Cancer Institute (NCI)||Phase 1|